Table 3 Factors associated with clearance among men with a prevalent oral oncogenic HPV infection

From: Persistence and clearance of oral human papillomavirus among a multi-national cohort of men

Variable

Level

Transient (n = 83)

Persisted ≥ 6 months (n = 103)

Unadjusted HR (95% CI)

aHRa (95% CI)

Country

United States (n = 47)

21 (44.7%)

26 (55.3%)

REF

REF

Brazil (n = 66)

28 (42.4%)

38 (57.6%)

0.84 (0.56–1.29)

1.01 (0.55–1.86)

Mexico (n = 73)

30 (41.1%)

43 (58.9%)

0.85 (0.56–1.28)

1.57 (0.83–2.97)

Age Tertile (years)*

17–27 (n = 42)

24 (57.1%)

18 (42.9%)

REF

REF

28–38 (n = 75)

34 (45.3%)

41 (54.7%)

0.75 (0.49–1.14)

0.75 (0.44–1.26)

>39 (n = 69)

21 (30.4%)

48 (69.6%)

0.68 (0.45–1.04)

0.57 (0.34–0.96)

Race

Black (n = 22)

10 (45.5%)

12 (54.5%)

REF

 

White (n = 91)

39 (42.9%)

52 (57.1%)

1.44 (0.84–2.48)

 

Otherb (n = 69)

29 (42.0%)

40 (58.0%)

1.18 (0.68–2.07)

 

Ethnicity

Hispanic (n = 94)

39 (41.5%)

55 (58.5%)

REF

 

Non-Hispanic (n = 81)

36 (44.4%)

45 (55.6%)

0.90 (0.64–1.25)

 

Marital status

Single/Never married (n = 70)

32 (45.7%)

38 (54.3%)

REF

 

Married/Cohabiting (n = 91)

41 (45.1%)

50 (54.9%)

0.81 (0.57–1.15)

 

Divorced/Separated/Widowed (n = 24)

6 (25.0%)

18 (75.0%)

0.73 (0.43–1.23)

 

Education (years)

≤12 (n = 89)

33 (37.1%)

56 (62.9%)

REF

REF

13–15 (n = 34)

18 (52.9%)

16 (47.1%)

1.32 (0.85–2.05)

1.77 (0.92–3.42)

≥16 (n = 62)

28 (45.2%)

34 (54.8%)

1.03 (0.71–1.48)

1.02 (0.65–1.60)

Smoking status

Never smoked (n = 71)

33 (46.5%)

38 (53.5%)

REF

 

Ever smoked (n = 53)

18 (34.0%)

35 (66.0%)

0.90 (0.60–1.34)

 

Current smoker (n = 56)

27 (48.2%)

29 (51.8%)

1.15 (0.78–1.70)

 

Alcohol intake (# drinks per month)

0 (n = 39)

16 (41.0%)

23 (59.0%)

REF

 

1–30 (n = 75)

32 (42.7%)

43 (57.3%)

1.04 (0.67–1.61)

 

≥31 (n = 64)

29 (37.7%)

35 (34.7%)

1.16 (0.75–1.80)

 

Lifetime number of female sexual partners categories

0–2 (n = 22)

10 (45.5%)

12 (54.5%)

REF

REF

3–11 (n = 53)

23 (43.4%)

30 (56.6%)

1.37 (0.75–2.469)

2.05 (1.06–3.97)

≥12 (n = 89)

39 (43.8%)

50 (56.2%)

1.29 (0.73–2.29)

2.14 (1.07–4.30)

New female sex partners in past 6 months

0 (n = 50)

21 (42.0%)

29 (58.0%)

REF

 

1 (n = 71)

28 (39.4%)

43 (60.6%)

1.10 (0.72–1.66)

 

≥2 (n = 58)

26 (44.8%)

32 (55.2%)

1.15 (0.75–1.76)

 

Lifetime number of male sexual partners categories

0 (n = 147)

63 (42.9%)

84 (57.1%)

REF

REF

1–2 (n = 15)

6 (40.0%)

9 (60.0%)

0.70 (0.38–1.31)

0.72 (0.32–1.64)

≥3 (n = 18)

9 (50.0%)

9 (50.0%)

1.44 (0.85–2.44)

2.15 (0.99–4.64)

New male sex partners in past 6 months

0 (n = 165)

71 (43.0%)

94 (57.0%)

REF

 

1 (n = 6)

4 (66.7%)

2 (33.3%)

1.21 (0.49–2.96)

 

≥2 (n = 11)

4 (36.4%)

7 (63.6%)

1.38 (0.72–2.64)

 

Frequency of oral sex given in past 6 months

None (n = 50)

25 (50.0%)

25 (50.0%)

REF

REF

1–6 times (n = 56)

24 (42.9%)

32 (57.1%)

0.82 (0.53–1.24)

0.72 (0.45–1.16)

≥7 times (n = 42)

16 (38.1%)

26 (61.9%)

0.79 (0.50–1.24)

0.54 (0.31–0.94)

Ever had gingivitis

No (n = 162)

72 (44.4%)

90 (55.6%)

REF

 

Yes (n = 14)

5 (35.7%)

9 (64.3%)

1.62 (0.93–2.83)

 

Number of teeth extracted due to oral disease

0 (n = 119)

58 (48.7%)

61 (51.3%)

REF

 

≥1 (n = 56)

19 (33.9%)

37 (66.1%)

0.78 (0.55–1.12)

 
  1. *P < 0.05 when conducting a two-sided Pearson’s Chi-squared test or Wilcoxon rank sum test to test for differences in distribution between transient and >6month persistent infections.
  2. aHazard ratio is reported for the variables that remained after backwards elimination at alpha = 0.20 using Cox proportional hazards model for likelihood of clearing an oral oncogenic hrHPV infection.
  3. bOther race includes American Indian, Alaska Native, Native Hawaiian, Asian/Pacific Islander, and mixed race.